TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04132089

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: capABILITY
Description: All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: capABILITY
Description: All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
Study: NCT03204487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 15µg/ml
Description: Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
Study: NCT01043562

Intervention type: DIAGNOSTIC_TEST
Intervention: Defibrillator threshold testing
Description: Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.

Intervention type: OTHER
Intervention: Observation of post-shock intrinsic cardiac rhythm
Description: Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole \>4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a \>10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
Study: NCT00526565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique
Description: Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
Study: NCT01772147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 62.5mcg
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 125mcg
Description: Inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation powder
Study: NCT00747721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
Study: NCT00526565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support
Description: The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
Study: NCT00674856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod
Description: 750mg
Study: NCT03034473

Intervention type: OTHER
Group type: OTHER
Intervention: Translational Research and multimodal treatment
Description: Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\].
Study: NCT00909714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator to apply tDCS
Description: Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator to apply Sham tDCS
Description: Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
Study: NCT01934075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health treatment
Description: 6 sessions of individual mental health counseling.
Study: NCT01626625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells + hydroxy apatite
Description: patient will be transplanted with stem cells and hydroxyapatite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autograft taken from iliac crest
Description: patient will be transplanted with autograft
Study: NCT03094676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
Study: NCT03685292

Intervention type: BEHAVIORAL
Intervention: Behavioral Advisory System
Description: Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.

Intervention type: BEHAVIORAL
Intervention: Behavioral Advisory System
Description: Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.

Intervention type: BEHAVIORAL
Intervention: Behavioral Advisory System
Description: Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.

Intervention type: DRUG
Intervention: Behavioral Treatment
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.

Intervention type: DRUG
Intervention: Behavioral Treatment
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.

Intervention type: DRUG
Intervention: Behavioral Treatment
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.

Intervention type: DEVICE
Intervention: Behavioral Division
Description: This study is relative to minimal contact control (MCC).

Intervention type: DEVICE
Intervention: Behavioral Division
Description: This study is relative to minimal contact control (MCC).

Intervention type: DEVICE
Intervention: Behavioral Division
Description: This study is relative to minimal contact control (MCC).
Study: NCT02274064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview and Implementation Intention
Description: Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
Study: NCT04038177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Superset strength training
Description: Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strength training
Description: Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
Study: NCT04253431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoJect Dual S lancing device (Menarini)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlet 28G lancets (Bayer)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar Ultra-Thin 33G lancets (Sanofi Aventis)
Study: NCT01500213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: 200 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 10 mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 10 mcg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO and 8 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO and 8 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) o mg PO
Study: NCT00564044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: excision of the protruding mesh and its surrounding vaginal tissue
Description: A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
Study: NCT03768700

Intervention type: OTHER
Intervention: Data gathering
Description: Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
Study: NCT02306694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advate
Description: Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
Study: NCT02099279

Intervention type: DEVICE
Intervention: echocardiography examination
Description: patients underwent echocardiography examination
Study: NCT04297852

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegan drink
Description: Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo drink Dose: 500 mL a day
Study: NCT03897933

Intervention type: PROCEDURE
Intervention: Erector Spinae Plane block ( Group I)
Description: ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Intervention type: PROCEDURE
Intervention: non- blocked Group (GROUP II)
Description: This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study: NCT03186859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) surgery
Description: RYGB operation using surgeons' standard technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy (SG) surgery
Description: SG surgery using surgeons' standard technique
Study: NCT02428374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus clopidogrel
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus clopidogrel
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus clopidogrel
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus ticagrelor
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus ticagrelor
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus ticagrelor
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus clopidogrel
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus clopidogrel
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus clopidogrel
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus ticagrelor
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus ticagrelor
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus ticagrelor
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Study: NCT03744845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
Study: NCT03199612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
Study: NCT04676685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730-matched placebo
Description: E2730-matched placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730-matched placebo
Description: E2730-matched placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730-matched placebo
Description: E2730-matched placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730-matched placebo
Description: E2730-matched placebo capsules.
Study: NCT02877719

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
Study: NCT00793546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
Study: NCT05481268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping Group
Description: In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Group
Description: In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
Study: NCT06205173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot compressing
Description: The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold compressing
Description: The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
Study: NCT00825526

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR) Therapy
Description: The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Therapy
Description: The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress